Oystershell has come to an agreement with Bayer HealthCare LLC to acquire RID®, one of the leading brands in lice treatment in the US. 

RID® is known for its strong consumer brand awareness, high levels of professional endorsement and its well-respected brand logo and attributes.  In 2019, RID® achieved 25 million USD in retail sales and is the #2 brand in the US lice treatment market.

The U.S. Food and Drug Administration has approved Sklice to treat head lice for nonprescription, or over-the-counter (OTC) use. The FDA initially approved Sklice (ivermectin) lotion, 0.5% for the treatment of head lice infestation in patients 6 months of age and older as a prescription drug in February 2012.

Nuvo Pharmaceuticals have entered into an agreement with Heumann Pharma & Co GmBH Generica KC (Heumann) for the exclusive right to distribute, market and sell Resultz in Germany. Headquarterd in Nuremberg, Heumann is part of the Torrent Pharma Group.

A report by Jan Rainey published on April 29th 2018, suggests that NUVO PHARMACEUTICALS INC ORDINARY SHARES (OTCMKTS: NRIFF) had an increase of 1540% in short interest.

Nuvo Pharmaceuticals announced that it had acquired the global rights for Resultz, a head lice treatment from Piedmont Pharmaceuticals.